A Double-Layered Covered Biliary Metal Stent for the Management of Unresectable Malignant Biliary Obstruction: A Multicenter Feasibility Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The covered self-expandable metal stent (CMS) was developed to prevent tumor ingrowth-induced stent occlusion during the treatment of malignant biliary obstruction. However, complications such as cholecystitis, pancreatitis, and stent migration can occur after the endoscopic insertion of CMSs. The aim of the present study was to assess the efficacy and safety of a double-layered CMS (DCMS) for the management of malignant bile duct obstruction. Methods: DCMSs were endoscopically introduced into 59 patients with unresectable malignant extrahepatic biliary obstruction at four tertiary referral centers, and the patient medical records were retrospectively reviewed. Results: Both the technical and functional success rates were 100%. Procedure-related complications including pancreatitis, cholangitis, stent migration, and liver abscess occurred in five patients (8.5%). The median follow-up period was 265 days (range, 31 to 752 days). Cumulative stent patency rates were 68.2% and 40.8% at 6 and 12 months, respectively. At the final follow-up, the rate of stent occlusion was 33.9% (20/59), and the median stent patency period was 276 days (range, 2 to 706 days). Conclusions: The clinical outcomes of DCMSs were comparable to the outcomes previously reported for CMSs with respect to stent patency period and complication rates.
Abstract
Background/Aims: The covered self-expandable metal stent (CMS) was developed to prevent tumor ingrowth-induced stent occlusion during the treatment of malignant biliary obstruction. However, complications such as cholecystitis, pancreatitis, and stent migration can occur after the endoscopic insertion of CMSs. The aim of the present study was to assess the efficacy and safety of a double-layered CMS (DCMS) for the management of malignant bile duct obstruction. Methods: DCMSs were endoscopically introduced into 59 patients with unresectable malignant extrahepatic biliary obstruction at four tertiary referral centers, and the patient medical records were retrospectively reviewed. Results: Both the technical and functional success rates were 100%. Procedure-related complications including pancreatitis, cholangitis, stent migration, and liver abscess occurred in five patients (8.5%). The median follow-up period was 265 days (range, 31 to 752 days). Cumulative stent patency rates were 68.2% and 40.8% at 6 and 12 months, respectively. At the final follow-up, the rate of stent occlusion was 33.9% (20/59), and the median stent patency period was 276 days (range, 2 to 706 days). Conclusions: The clinical outcomes of DCMSs were comparable to the outcomes previously reported for CMSs with respect to stent patency period and complication rates.
참고문헌 (19)
- Speer AG, "Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice", Lancet, 2, pp.57~62 (1987)
- Petersen BT, "A multicenter, prospective study of a new fully covered expandable metal biliary stent for the palliative treatment of malignant bile duct obstruction", Gastroenterol Res Pract, 2013, pp.642428~ (2013)
- Terruzzi V, "Prospective randomized trial comparing Tannenbaum Teflon and standard polyethylene stents in distal malignant biliary stenosis", Gastrointest Endosc, 51, pp.23~27 (2000)
- Soehendra N, "Palliative biliary duct drainage:a new method for endoscopic introduction of a new drain", Dtsch Med Wochenschr, 104, pp.206~207 (1979)
- England RE, "A prospective randomised multicentre trial comparing 10 Fr Teflon Tannenbaum stents with 10 Fr polyethylene Cotton-Leung stents in patients with malignant common duct strictures", Gut, 46, pp.395~400 (2000)
- Jaganmohan S, "Self-expandable metal stents in malignant biliary obstruction", Expert Rev Gastroenterol Hepatol, 6, pp.105~114 (2012)
- Shim CS, "Preliminary results of a new covered biliary metal stent for malignant biliary obstruction", Endoscopy, 30, pp.345~350 (1998)
- Isayama H, "A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction", Gut, 53, pp.729~734 (2004)
- Fumex F, "Similar performance but higher cholecystitis rate with covered biliary stents: results from a prospective multicenter evaluation", Endoscopy, 38, pp.787~792 (2006)
- Park do H, "Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis", Clin Gastroenterol Hepatol, 4, pp.790~796 (2006)
- Nakai Y, "Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction", Gastrointest Endosc, 62, pp.742~748 (2005)
- Park do H, "Anchoring flap versus flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a multicenter, prospective, comparative pilot study (with videos)", Gastrointest Endosc, 73, pp.64~70 (2011)
- Isayama H, "Management of distal malignant biliary obstruction with the ComVi stent, a new covered metallic stent", Surg Endosc, 24, pp.131~137 (2010)
- Yoon WJ, "A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction", Gastrointest Endosc, 63, pp.996~1000 (2006)
- Suk KT, "Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction", Gastrointest Endosc, 64, pp.522~529 (2006)
- Telford JJ, "A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction", Gastrointest Endosc, 72, pp.907~914 (2010)
- Kullman E, "Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study", Gastrointest Endosc, 72, pp.915~923 (2010)
- Kahaleh M, "Efficacy and complications of covered Wallstents in malignant distal biliary obstruction", Gastrointest Endosc, 61, pp.528~533 (2005)
- Perri V, "Prospective evaluation of the partially covered nitinol “ComVi” stent for malignant non hilar biliary obstruction", Dig Liver Dis, 45, pp.305~309 (2013)